Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28214068 | 1.00 | FFAR3 (0.62) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL3790146 | 0.97 | — | — | |
| Piperazine SCHEMBL28047208 | 0.94 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL29104606 | 0.94 | — | — | |
| Piperidine SCHEMBL6861563 | 0.88 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Pyrrolidine SCHEMBL28213560 | 0.88 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL28087121 | 0.88 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Piperidine SCHEMBL1274941 | 0.88 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Pyrrolidine SCHEMBL10413119 | 0.88 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL9615008 | 0.85 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601858-A1 | METHOD FOR THREE-DIMENSIONAL PRINTING OF FIBER COMPOSITE MATERIALS | MOI COMPOSITES S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| WO-2024079597-A1 | METHOD FOR THREE-DIMENSIONAL PRINTING OF FIBER COMPOSITE MATERIALS | MOI COMPOSITES S.R.L. (IT) | 2024-04-18 | — | — | WO | claimed |
| CN-113998724-A | One-step method for fixing carbon by gypsum and regulating and controlling particle size of product | 南京工程学院 | 2022-02-01 | — | — | CN | claimed |
| EP-4601858-A1 | METHOD FOR THREE-DIMENSIONAL PRINTING OF FIBER COMPOSITE MATERIALS | MOI COMPOSITES S.r.l. (IT) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024079597-A1 | METHOD FOR THREE-DIMENSIONAL PRINTING OF FIBER COMPOSITE MATERIALS | MOI COMPOSITES S.R.L. (IT) | 2024-04-18 | — | — | WO | disclosed |
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-26 | — | — | US | disclosed |
| US-20230135413-A1 | CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED INK, STORED CONTAINER, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING APPARATUS, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING METHOD, CURED PRODUCT, AND DECORATED BODY | RICOH COMPANY, LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| CN-113998724-A | One-step method for fixing carbon by gypsum and regulating and controlling particle size of product | 南京工程学院 | 2022-02-01 | — | — | CN | disclosed |
| US-10829631-B2 | Composition, accommodating unit, image forming device, and image forming method | RICOH COMPANY, LTD. (JP) | 2020-11-10 | — | — | US | disclosed |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| CN-109862963-A | SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES | 优美科股份公司及两合公司 | 2019-06-07 | — | — | CN | disclosed |
| US-6861435-B2 | Urokinase inhibitors | PENTAPHARM AG (CH) | 2005-03-01 | — | — | US | disclosed |
| US-20040110831-A1 | Urokinase inhibitors | WILEX AG (DE) | 2004-06-10 | — | — | US | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1310250-A1 | Use of the compound 2-methoxyphenyl-1-methyl-5P-methylbenzoyl-pyrrol-2-acetamido acetate for the production of an antiinflammatory drug with prevention of gastric hypersecretion and renal impairment | MEDOSAN RICERCA S.r.l. (IT) | 2003-05-14 | — | — | EP | disclosed |
| EP-1024807-B1 | USE OF THE COMPOUND 2-METHOXYPHENYL-1-METHYL-5P-METHYLBENZOYL-PYRROL-2-ACETAMIDO ACETATE FOR THE PRODUCTION OF AN ANTI-INFLAMMATORY DRUG WITH PREVENTION OF GASTRIC HYPERSECRETION AND RENAL IMPAIRMENT | MEDOSAN RICERCA SRL (IT) | 2003-04-16 | — | — | EP | disclosed |
| US-6180658-B1 | ADMINISTERING 2-METHOXYPHENYL-1-METHYL-5-P-METHYLBENZOYLPYRROLE-2-ACETAMIDEA CETATE | MEDOSAN RICERCA S.R.L. (IT) | 2001-01-30 | — | — | US | disclosed |
| EP-1024807-A1 | USE OF THE COMPOUND 2-METHOXYPHENYL-1-METHYL-5P-METHYLBENZOYL-PYRROL-2-ACETAMIDO ACETATE FOR THE PRODUCTION OF AN ANTI-INFLAMMATORY DRUG WITH PREVENTION OF GASTRIC HYPERSECRETION AND RENAL IMPAIRMENT | MEDOSAN RICERCA S.r.l. (IT) | 2000-08-09 | — | — | EP | disclosed |
| US-5889041-A | ADMINISTERING AMTOLMETIN GUACIL | MEDOSAN RICERCA S.R.L. (IT) | 1999-03-30 | — | — | US | disclosed |
| WO-1999007363-A1 | USE OF THE COMPOUND 2-METHOXYPHENYL-1-METHYL-5P-METHYLBENZOYL-PYRROL-2-ACETAMIDO ACETATE FOR THE PRODUCTION OF AN ANTI-INFLAMMATORY DRUG WITH PREVENTION OF GASTRIC HYPERSECRETION AND RENAL IMPAIRMENT | MEDOSAN, RICERCA S.R.L. (IT) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | NPC1L1, NPC1, CETP | FFAR3 387/4885HDAC3 1083/4885HDAC1 1471/4885 |
| US-20040110831-A1 | Urokinase inhibitors | RNASE1, PLAUR, PLAU | FFAR3 927/4885HDAC3 3827/4885HDAC1 2255/4885 |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | FFAR3 387/4885HDAC3 1083/4885HDAC1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.